S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Price, News & Analysis

$2.42
+0.12 (+5.22%)
(As of 03/27/2024 ET)
Today's Range
$2.28
$2.44
50-Day Range
$2.02
$2.85
52-Week Range
$1.43
$8.65
Volume
2.58 million shs
Average Volume
4.39 million shs
Market Capitalization
$272.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.29

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
283.7% Upside
$9.29 Price Target
Short Interest
Bearish
22.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
-0.16mentions of Coherus BioSciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.56) to $0.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

229th out of 939 stocks

Biological Products, Except Diagnostic Industry

29th out of 151 stocks

CHRS stock logo

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

CHRS Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Q4 2023 Coherus BioSciences Inc Earnings Call
Recap: Coherus BioSciences Q4 Earnings
Coherus BioSciences Inc (CHRS)
Coherus Biosciences Amends Loan Terms with Biopharma
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
3/27/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
299
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$12.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+292.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-237,890,000.00
Pretax Margin
-92.62%

Debt

Sales & Book Value

Annual Sales
$257.24 million
Book Value
($1.74) per share

Miscellaneous

Free Float
100,327,000
Market Cap
$272.76 million
Optionable
Optionable
Beta
0.54

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 69)
    Chairman, President & CEO
    Comp: $1.79M
  • Mr. Bryan J. McMichael (Age 46)
    Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Ms. Jami Taylor
    Vice President of Investor Relations
  • Cheston Turbyfill
    Vice President of Communications
  • Mr. Scott Saywell
    Executive Vice President of Corporate Development
  • Ms. Rebecca Sunshine (Age 61)
    Chief Human Resources Officer
  • Mr. Michael Chen
    Senior Vice President of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 55)
    Chief Commercial Officer
  • Dr. Theresa M. Lavallee Ph.D. (Age 58)
    Chief Development Officer & Chairman of Scientific Advisory Board

CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price target for 2024?

6 brokerages have issued 12 month price objectives for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $12.00. On average, they expect the company's share price to reach $9.29 in the next twelve months. This suggests a possible upside of 283.7% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2024?

Coherus BioSciences' stock was trading at $3.33 at the beginning of 2024. Since then, CHRS stock has decreased by 27.3% and is now trading at $2.42.
View the best growth stocks for 2024 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 25,910,000 shares, an increase of 7.1% from the February 29th total of 24,200,000 shares. Based on an average daily trading volume, of 5,770,000 shares, the days-to-cover ratio is presently 4.5 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Monday, March, 6th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company had revenue of $45.35 million for the quarter, compared to the consensus estimate of $45.72 million. During the same quarter last year, the business earned ($0.60) earnings per share.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

What guidance has Coherus BioSciences issued on next quarter's earnings?

Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $260.0 million-$260.0 million, compared to the consensus revenue estimate of $260.5 million.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.30%), Vanguard Group Inc. (9.30%), Peregrine Capital Management LLC (0.98%), Charles Schwab Investment Management Inc. (0.69%), Nuveen Asset Management LLC (0.68%) and Cubist Systematic Strategies LLC (0.35%). Insiders that own company stock include Dennis M Lanfear, James Healy and Mcdavid Stilwell.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
This page (NASDAQ:CHRS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners